Rapid clearance of mepolizumab-resistant bronchial mucus plugs in allergic bronchopulmonary aspergillosis with benralizumab treatment

Allergol Int. 2020 Oct;69(4):636-638. doi: 10.1016/j.alit.2020.03.003. Epub 2020 Apr 1.

Authors

Katsuyoshi Tomomatsu¹, Yasuteru Sugino², Naoki Okada¹, Jun Tanaka¹, Tsuyoshi Oguma¹, Koichiro Asano³

Affiliations

¹ Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Isehara, Japan.
² Department of Respiratory Medicine, Toyota Memorial Hospital, Toyota, Japan.
³ Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Isehara, Japan. Electronic address: ko-asano@tokai-u.jp.

PMID: 32247541
DOI: 10.1016/j.alit.2020.03.003

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Anti-Asthmatic Agents / administration & dosage
Anti-Asthmatic Agents / adverse effects
Anti-Asthmatic Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use*
Aspergillosis, Allergic Bronchopulmonary / diagnostic imaging
Aspergillosis, Allergic Bronchopulmonary / drug therapy*
Aspergillosis, Allergic Bronchopulmonary / pathology*
Biomarkers
Bronchi / diagnostic imaging
Bronchi / drug effects*
Bronchi / pathology*
Drug Resistance
Female
Humans
Immunoglobulin E / immunology
Male
Mucus* / drug effects
Tomography, X-Ray Computed
Treatment Outcome

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
Biomarkers
Immunoglobulin E
benralizumab
mepolizumab